ADCT ADC Therapeutics SA
Pharmaceutical Preparations · NYSE · SEC CIK 1771910 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.8%
TTM net income YoY51.3%
TTM EPS YoY67.4%
Revenue 3-yr CAGR-11.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-97.7%
Net margin-95.7%
FCF margin-118.5%
EBITDA margin—
Returns
ROE—
ROA-29.8%
ROIC (approx.)—
Asset turnover0.31x
Leverage & solvency
Liabilities / assets197.4%
Debt / equity—
Current ratio3.05x
Interest coverage-1.58x
Cash quality & payout
Operating cash flow / net income1.24x
Accruals ratio7.1%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $21.72M | $19.25M | $20.85M | $23.06M | $16.43M | $18.84M | $23.03M | $16.91M |
| R&D expense | $14.74M | $17.37M | $19.88M | $18.18M | $26.80M | $30.09M | $28.93M | $27.10M |
| SG&A expense | $10.74M | $9.70M | $9.90M | $9.46M | $8.33M | $8.82M | $9.96M | $9.62M |
| Operating income | -$14.35M | -$25.41M | -$25.25M | -$17.92M | -$30.97M | -$44.15M | -$28.46M | -$32.44M |
| Interest expense | $13.73M | $13.51M | $12.35M | $13.01M | $13.39M | $13.00M | $12.23M | $11.92M |
| Pretax income | -$25.30M | -$16.57M | -$32.97M | -$6.81M | -$40.97M | -$55.39M | -$38.44M | -$31.05M |
| Income tax | $0 | $0 | $0 | -$404,000 | $0 | $1.25M | $165,000 | -$321,000 |
| Net income | -$25.30M | -$16.57M | -$32.97M | -$6.41M | -$40.97M | -$56.65M | -$38.60M | -$30.73M |
| EBITDA | — | — | — | -$17.92M | -$30.97M | -$43.78M | -$28.12M | -$32.09M |
| EPS (basic) | -0.16 | -0.11 | -0.21 | — | -0.30 | -0.50 | -0.36 | — |
| EPS (diluted) | -0.16 | -0.11 | -0.21 | — | -0.30 | -0.50 | -0.36 | — |
| Weighted avg. shares (diluted) | 155.41M | 155.02M | 154.14M | — | 136.45M | 113.74M | 107.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $189.20M | $219.11M | $231.01M | $261.34M | $234.74M | $264.56M | $194.70M | $250.87M |
| Inventory | $5.63M | $4.93M | $4.78M | $4.18M | $18.04M | $17.76M | $17.45M | $2.25M |
| Current assets | $238.58M | $261.71M | $276.77M | $306.33M | $287.15M | $318.75M | $257.99M | $291.25M |
| PP&E, net | — | — | — | $0 | $0 | $1,000 | $5.16M | $5.08M |
| Total assets | $255.86M | $279.38M | $291.50M | $323.15M | $289.76M | $321.56M | $272.54M | $321.98M |
| Current liabilities | $78.12M | $86.33M | $67.63M | $70.16M | $62.04M | $64.60M | $57.79M | $80.47M |
| Short-term debt | $7.80M | $6.18M | $4.63M | $3.00M | — | — | — | $0 |
| Total liabilities | $505.04M | $507.58M | $507.87M | $508.98M | $527.94M | $520.75M | $510.76M | $524.62M |
| Shareholders' equity | -$249.17M | -$228.21M | -$216.38M | -$185.83M | -$238.18M | -$199.18M | -$238.22M | -$202.64M |
| Shares outstanding | 127.74M | 127.44M | 127.17M | 125.75M | 112.63M | 112.50M | 99.18M | 98.86M |
| Cash flow statement | ||||||||
| Operating cash flow | -$27.88M | -$11.81M | -$29.71M | -$31.12M | -$29.63M | -$24.09M | -$56.33M | -$21.85M |
| Capital expenditure | $0 | $0 | $32,000 | $0 | $0 | $0 | $264,000 | $90,000 |
| Free cash flow | -$27.88M | -$11.81M | -$29.74M | -$31.12M | -$29.63M | -$24.09M | -$56.60M | -$21.94M |
| Investing cash flow | $0 | $0 | -$32,000 | $659,000 | $0 | $0 | -$264,000 | -$90,000 |
| Financing cash flow | -$2.10M | -$99,000 | -$583,000 | $57.09M | -$198,000 | $93.78M | $271,000 | -$1.12M |
| Depreciation & amortization | — | — | — | $0 | $0 | $362,000 | $342,000 | $341,000 |
| Stock-based compensation | $4.09M | $4.55M | $2.44M | $673,000 | $2.00M | $1.81M | $2.42M | $1.62M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.